Physician profile
Thomas Mahl
NPI 1780633412
$1,457.57
in general payments reported to CMS, 2019-2025
10 companies · $254 in 2025
The $254 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.33 · 2020: $228 · 2021: $391 · 2022: $438 · 2023: $135 · 2025: $254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $379 · Education: $10.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $379.41 |
| Education | $10.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $487.01 | 2021-2025 | |
| Janssen Biotech, INC. | $358.78 | 2020-2025 | Tremfya |
| Pentax of America, INC. | $238.42 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $135.31 | 2023 | Terlivaz |
| Erbe USA INC | $88.00 | 2021 | |
| Celgene Corporation | $75.95 | 2021-2022 | |
| Boston Scientific Corporation | $24.70 | 2020 | |
| Braintree Laboratories, INC. | $22.48 | 2021 | |
| Orexo US, INC. | $15.59 | 2021 | |
| Cook Medical LLC | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Mahl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.